Initiator Pharma: CTA submitted for phase IIa study in vulvodynia - Redeye

Redeye comments on Initiator Pharma’s announcement that it has submitted a CTA to the UK authorities for a phase IIa proof-of-concept study of pudafensine in vulvodynia. We view this as an important operational milestone that broadens the company’s focus into female indications, supported by secured financing and a clear clinical path, and believe positive results could unlock substantial value in an underserved market.

Länk till analysen i sin helhet: https://www.redeye.se/research/1126541/initiator-pharma-cta-submitted-for-phase-iia-study-in-vulvodynia?utm_source=finwire&utm_medium=RSS